share_log

HC Wainwright & Co. Maintains Buy on Revance Therapeutics, Raises Price Target to $42

Benzinga Real-time News ·  Jan 26, 2023 06:15

HC Wainwright & Co. analyst Douglas Tsao maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and raises the price target from $29 to $42.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment